First-in-human clinical trial for a vaccine to treat opioid use disorders enrolls first patients
The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by researchers at the University of Minnesota Medical School.
Funded by a grant from the National Institutes of Health, the trial will test the safety and potential efficacy of a vaccine that is designed to selectively prevent the euphoric and toxic effects of oxycodone.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
More News: Clinical Trials | Grants | National Institutes of Health (NIH) | Oxycodone | OxyContin | Pharmaceuticals | Study | Toxicology | University of Minnesota | Vaccines